Screener
Theravance Biopharma TBPH Operating Income
Operating Income at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Theravance Biopharma in its filing.
Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.
The source filing: Theravance Biopharma’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 9:00 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001104659-26-056760
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Selling, general and administrative (1) | 17,720 | 18,370 |
| Restructuring expenses (1) (2) | 3,633 | — |
| Total expenses | 27,182 | 29,822 |
| Loss from operations | (9,483) | (14,434) |
| Interest expense (non-cash) | — | (643) |
| Interest and other income, net | 3,013 | 939 |
| Loss before income taxes | (6,470) | (14,138) |
| Provision for income tax benefit | 1,537 | 559 |
Item 1. Financial Statements (unaudited)
FAQ
- What is Theravance Biopharma's operating income?
- Theravance Biopharma (TBPH) reported operating income of -$9.48M in Q1 2026.
- How has Theravance Biopharma's operating income changed year-over-year?
- Theravance Biopharma's operating income increased by 34.3% year-over-year, from -$14.43M to -$9.48M.
- What is the long-term trend for Theravance Biopharma's operating income?
- Over 4 years (2021 to 2025), Theravance Biopharma's operating income has grown at a -65.6% compound annual growth rate (CAGR), from -$257.78M to -$3.6M.
- What does operating income mean?
- Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.
Ask your AI about Theravance Biopharma's operating income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude